Evidence map›Paper›PMID 33831754›Full record

ArticleCellular immunology2021

Hybrid cytokine IL233 renders protection in murine acute graft vs host disease (aGVHD).

Rajkumar Venkatadri, Vikram Sabapathy, Murat Dogan, Rohan Sharma, Saleh Mohammad, Charles S Via, Rahul Sharma

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rajkumar VenkatadriCenter for Immunity, Inflammation and Regenerative Medicine (CIIR), Division of Nephrology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Vikram SabapathyCenter for Immunity, Inflammation and Regenerative Medicine (CIIR), Division of Nephrology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Murat DoganCenter for Immunity, Inflammation and Regenerative Medicine (CIIR), Division of Nephrology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Rohan SharmaCenter for Immunity, Inflammation and Regenerative Medicine (CIIR), Division of Nephrology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Saleh MohammadCenter for Immunity, Inflammation and Regenerative Medicine (CIIR), Division of Nephrology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Charles S ViaDepartment of Pathology, Uniformed Services University, Bethesda, MD, USA.
Rahul SharmaCenter for Immunity, Inflammation and Regenerative Medicine (CIIR), Division of Nephrology, Department of Medicine, University of Virginia, Charlottesville, VA, USA. Electronic address: rs3wn@virginia.edu.
University of Virginia · USUniformed Services University of the Health Sciences · US

Funding

Regulatory T Cells in Acute Kidney InjuryR01DK104963 · NIDDK · UNIVERSITY OF VIRGINIA · PI SHARMA, RAHUL · 2016 to 2020
$1.8M
Targeting Treg for Therapy of Lupus GlomerulonephritisR01DK105833 · NIDDK · UNIVERSITY OF VIRGINIA · PI FU, SHU MAN, SHARMA, RAHUL · 2016 to 2019
$1.4M
NIDDK NIH HHS R01 DK104963NIDDK NIH HHS R01 DK105833
6 · The paper itself

Abstract

Previously, we generated IL233, a hybrid cytokine composed of interleukin (IL)-2 and IL-33, with better therapeutic potential than either cytokine in multiple inflammatory diseases, in part through promoting T-regulatory cells (Tregs). Here we test the potential of IL233 pretreatment in a murine model of excessive Th1 activation, the parent-into-F1 model of acute GVHD (aGVHD). Five days of IL233 pretreatment of the recipients blocked or delayed the aGVHD-linked loss of B cells as seen in either the peripheral blood (day-11) or lymph nodes (day-14). IL233 pretreatment also prevented the expansion of donor CD8 T-cells in blood and LN at day-14 and significantly reduced day-14 serum IFNγ and TNFα compared to saline treated GVHD mice although, the level of Tregs did not statistically differ between saline and IL233-treated mice. Overall, the current study provides support for the use of IL233 as a therapeutic option in excessive Th1/CD8-driven conditions.

Indexed as

Bone Marrow TransplantationAnimalsB-LymphocytesCells, CulturedDisease Models, AnimalGraft vs Host DiseaseHumansInterferon-gammaInterleukin-2Interleukin-33Lymphocyte ActivationMiceMice, Inbred C57BLRecombinant Fusion ProteinsTh1 CellsT-Lymphocytes, RegulatoryInterferon-gammaInterleukin-2Interleukin-33Recombinant Fusion ProteinsTumor Necrosis Factor-alphaGVHDIL-2IL233IL-33InflammationTreg

Identifiers

PMID33831754
PMCPMC8128039
OpenAlexW3136346022

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.